As shown in this research, at the clinically relevant concentration (50, 100 and 200μM), ropivacaine inhibited the migration of esophageal cancer OE33, ESO26 and FLO-1 cells via decreasing the activities of GTPases of RhoA, Rac1 and Ras, and inhibiting the prenylation, which were independent of sodium channel. This evidence concerns the gene RAC1 and esophageal cancer.